CPI 1205Alternative Names: CPI1205
Latest Information Update: 27 Mar 2015
At a glance
- Originator Constellation Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action EZH2 enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B cell lymphoma
Most Recent Events
- 01 Mar 2015 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (unspecified route) (NCT02395601)